Navigation Links
Bionomics Achieves US$1 Million Milestone Payment from Genmab
Date:2/19/2008

s for cancer to the clinic."

The CEO of Genmab Lisa N Drakeman, PhD commented: "We are pleased to reach the next level of development with these targets and look forward to continuing the collaboration with Bionomics."

Professor Jan G J van de Winkel, PhD, Chief Scientific Officer of Genmab added: "This milestone has been reached following extensive studies by Genmab on the Bionomics targets. The work we have undertaken has confirmed and extended the work performed by Bionomics, further supporting their potential as new targets for therapeutic antibodies."

Bionomics has the rights and is actively developing a large number of additional proprietary proteins discovered through its angiogenesis program, including BNO69. In addition Bionomics' anti-cancer drug BNC105 will soon commence a Phase 1 clinical trial at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Western Hospital cancer centres in Melbourne for the treatment of solid tumours including breast, colon and prostate cancers. BNC105 was identified using the Angene(R) platform. Bionomics' Investigational New Drug (IND) submission for BNC105 was accepted by the US Food and Drug Administration in November 2007.

About Bionomics Limited:

Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' discovery and development activities are driven by its three technology platforms: Angene(R), the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore(R) is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX(R) is a set of novel technologies for the identification of drugs targeting ion channels for diseases of t
'/>"/>

SOURCE Bionomics Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
3. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
9. BioVascular Inc. Closes $10.87 Million Series C Financing
10. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
11. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Calif. , May 22, 2013 Advanced ... a medical device that will help alleviate the high ... targeted apheresis cartridge is expected to be the first ... cause of maternal and fetal death. Every ... the United States . It is characterized ...
(Date:5/22/2013)... 2013 Attorney Advertising -- Bronstein, Gewirtz & ... of purchasers of the securities of AMAG Pharmaceuticals, ... The investigation focuses on whether the Company and ... On May 22, 2013, Shares of AMAG dropped ... company announced in regulatory filing that it has ...
(Date:5/22/2013)... N.Y. , May 22, 2013  The Leukemia ... million to Valor Biotherapeutics, LLC, a joint venture ... pre-clinical development, manufacturing, and a Phase I clinical trial ... poor outcomes faced by many patients with indolent lymphomas ... Valor,s protein, IGN002, is a new ...
Breaking Medicine Technology:Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4
... Conference Call Scheduled for 9:00 AM ET ... Dendreon Corporation (Nasdaq:,DNDN) announced today that it ... Phase 3, randomized, double-blind, placebo-controlled IMPACT,(IMmunotherapy for ... trial designed to assess the safety and ...
... that drinking polyphenol-rich 100% Concord grape,juice was not ... body,weight, CONCORD, Mass., Oct. 6 Regular ... cause significant weight gain,was not associated with changes ... according to new data presented at the 49th ...
Cached Medicine Technology:Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3
(Date:5/23/2013)... (PRWEB) May 23, 2013 Hormones drive many ... muscle tone, fat build-up, sleep quality, sex drive, how productive ... are getting older are driven by declining hormone levels as ... dehydroepiandrosterone, is the most abundant foundation or base from which ... body gradually increase until about age 25, when we are ...
(Date:5/23/2013)... Each month Dwell magazine is filled ... and electric cars. Nowhere in America are these pages more ... car capital. Thankfully this June, Green Car Journal is bringing ... to Dwell on Design 2013 ( http://www.dwellondesign.com ), ... two days of Dwell on Design, June 21-22, attendees and ...
(Date:5/23/2013)... discovered that the daily clearance of neutrophils from the ... the bone marrow into the bloodstream, according to a ... Neutrophils are leukocytes (white blood cells) that defend the ... To perform their function, these cells release toxic substances ... of these substances in the wrong place by damaged ...
(Date:5/23/2013)... May 23, 2013 Professional Insurance Plans, ... the nation to celebrate Fibromyalgia Education and Awareness Month. ... chiropractors across the country, the agency feels that it ... of this syndrome that affects an estimated 10 million ... Association , the definition of Fibromyalgia (FM) is, “a ...
(Date:5/23/2013)... 23, 2013 Diversity Focus announced today that ... expanded understanding of diversity. The results come from the ... from February-March of this year. 1198 qualified residents took part. ... up to its benchmark survey in 2008. , In ... the definition of diversity were race and ethnicity. But ...
Breaking Medicine News(10 mins):Health News:Health2Go Announces Research That DHEA Helps Depression 2Health News:Health2Go Announces Research That DHEA Helps Depression 3Health News:Health2Go Announces Research That DHEA Helps Depression 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5Health News:Discarded immune cells induce the relocation of stem cells 2Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2Health News:Diversity Focus Announces Results from the 2013 Creative Corridor Community Survey 2
... have successfully tested 10 new sugar-fat compounds they believe ... time with limited side effects. The new compounds were ... president of Taiwan's highest academic research body, the Academia ... of sugars. ,"This is an innovative strategy ...
... new survey this week at the annual SLEEP meeting ... having on healthcare professionals job performance and patient safety. ... than one quarter of nurses (27.23%) suffered from insomnia; ... asleep, and 55.38% suffered from a combination of both ...
... proteins present in blood that accurately identify colon cancer ... CCSA-3 and CCSA-4, suggest they could be used to ... ,"The reality is that many people are not ... Ph.D. "So, ideally we'd like to identify those with ...
... the bulges and fat has arrived in pharmacies across the ... FDA approved diet drug to be available over- the -counter ... been introduced to drugstore shelves with a new name and ... Alli. It has been introduced by the world GlaxoSmithKline Plc, ...
... the Saint Malo bay in western France, a bunch of ... half a dozen bottles hauled out of the bottom ... Village de Brissac-Quince -- had spent a year submerged 10 ... Solidor.,As per custom, the six wine-buffs swirled, sniffed and savoured ...
... the West. ,With the tremendous growth in mobile revolution, ... and numbers stored in its memory but yet nobody, other ... near and dear. ,In case they (the mobile users) ... the physicians attending on the injured or diseased get hold of ...
Cached Medicine News:Health News:Taiwan Researchers Claim Cancer Therapy Alternative 2Health News:Insomnia Affects Job Performance A New Survey 2Health News:Blood Test Reveals Colon Cancer Proteins 2Health News:Alli- a New Weapon for War Against the Bulges 2Health News:Sea Massage for French Wines 2Health News:Look Out for ICE in Emergency Situations 2
... catheters are available in a wide ... multi-electrode tip configurations and several curve ... handcrafted to precise and demanding specifications, ... A unique multi-step process incorporating proven ...
... offers a wide range of fixed curve ... needs of children and other patients with ... demanding specifications using only the finest materials. ... wire braiding and extrusion technologies results in ...
Inquiry 4Fr, 5Fr and 6Fr diagnostic electrophysiology catheters offer simple, precise distal control with it's patented Easy-Hand steering mechanism....
... Ankle/Brachial Index (ABI) testing, Nicolet Vascular has ... It includes a 10-minute compact disk ABI ... any computer with a CD drive. It ... ABI test, provides information on the materials ...
Medicine Products: